HMMR and chronic myelogenous leukemia, BCR-ABL1 positive: VX-680, showed anti-cancer activity in vivo in many solid cancers in preclinical experiment, and was demonstrated to inhibit multiple myeloma growth, especially in patients with RHAMM overexpression, and chronic myeloid leukemia (CML) with BCR-ABL mutations [17-19].